Showing results (251-260 of 259) with videos related to
Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 259 results.
The Journal of Biological Chemistry|November 29, 1996
AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1A L Akeson, C W Woods, L C Hsieh, et al.Clinical and Experimental Rheumatology|December 28, 1999
The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritisC H van Jaarsveld, E J ter Borg, J W Jacobs, et al.Nature|October 3, 2000
A chemical switch for inhibitor-sensitive alleles of any protein kinaseA C Bishop, J A Ubersax, D T Petsch, et al.Rheumatology (Oxford, England)|January 4, 2001
Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritisC H van Jaarsveld, Z N Jahangier, J W Jacobs, et al.Science (New York, N.Y.)|October 13, 2000
Blue-fluorescent antibodiesA Simeonov, M Matsushita, E A Juban, et al.Rheumatology (Oxford, England)|December 26, 2001
Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritisR N de Nijs, J W Jacobs, J W Bijlsma, et al.Proceedings of the National Academy of Sciences of the United States of America|July 9, 1996
High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide librariesS D Yanofsky, D N Baldwin, J H Butler, et al.Annals of the Rheumatic Diseases|June 2, 2000
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The NetherlandsC H van Jaarsveld, J W Jacobs, M J van der Veen, et al.Annals of Internal Medicine|April 15, 1996
The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trialA van der Heide, J W Jacobs, J W Bijlsma, et al.Pageof 26